文献速递胸部肿瘤放疗放疗物理与技术

治疗时长与不可切除III期NSCLC根治性放疗期间外周淋巴细胞计数变化相关

Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC.
PubMed 文献 · Radiat Oncol · 2019-05-27

本研究回顾115例接受不同剂量和分割方案根治性放化疗的不可切除III期NSCLC患者,分析分次方案和总治疗时间(OTT)对外周淋巴细胞减少的影响及其与预后的关系。结果显示54.8%患者发生严重淋巴细胞减少(SL),SL与更差的无进展生存和总生存相关;OTT在4周内的大分割放疗与SL风险显著降低相关。

要点

  • 根治性放疗期间54.8%的III期NSCLC患者发生严重淋巴细胞减少(TLC最低值<500 cells/μL)。
  • 严重淋巴细胞减少与更差的无进展生存(HR=0.544,P=0.010)和总生存(HR=0.463,P=0.011)相关。
  • OTT在4周内的大分割放疗与SL风险降低相关(OR=0.322,P=0.032)。

核心结论

  • 大分割放疗与根治性放疗期间严重淋巴细胞减少风险降低及生存改善显著相关。

研究设计与样本

  • 回顾性研究纳入115例接受根治性放化疗的不同剂量和分割方案的不可切除III期NSCLC患者,复习临床和实验室记录评估总淋巴细胞计数变化。

主要发现

  • 整个队列总淋巴细胞计数中位降低1300 cells/μL(IQR 950-1510 cells/μL)。
  • 63例(54.8%)发生严重淋巴细胞减少(TLC最低值<500 cells/μL),中位发生于放疗开始后第5周。
  • 严重淋巴细胞减少风险在前5周增加(OR=3.455,P=0.007),之后未见风险增加(OR=0.562,P=0.216)。
  • 放疗结束后2个月总淋巴细胞计数仍低于放疗前正常水平。
  • 无严重淋巴细胞减少患者的多因素分析显示无进展生存(HR=0.544,P=0.010)和总生存(HR=0.463,P=0.011)显著改善。

关键数值与推荐

  • 严重淋巴细胞减少定义为TLC最低值<500 cells/μL。
  • OTT在4周内的大分割放疗组严重淋巴细胞减少发生率为32.1%,OTT超过4周组为62.1%(P=0.006)。
  • 多因素分析显示OTT在4周内与严重淋巴细胞减少风险降低显著相关(OR=0.322,P=0.032)。

临床怎么用

  • 对不可切除III期NSCLC根治性放疗患者应关注外周淋巴细胞计数变化,尤其在前5周。
  • 考虑采用OTT在4周内的大分割放疗方案可能降低严重淋巴细胞减少风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To investigate the potential impact of fractionation regimes and overall treatment time (OTT) on lymphopenia during definitive radiotherapy (RT) and its associations with patient outcomes in non-small cell lung cancer (NSCLC). METHODS: Subjects consisted of 115 patients who had received definitive chemoradiation therapy (CRT) with different doses and fractions for unresectable stage III NSCLC. Clinical and laboratory records were reviewed to assess the changes in total lymphocyte counts (TLCs) during definitive RT. The associations of the TLCs with the clinical and treatment features, and outcomes were analyzed. RESULTS: The median reduction of TLCs in the entire cohort was 1300 cells/μL (interquartile range [IQR], 950-1510 cells/μL). Of all patients, 63 (54.8%) experienced severe lymphopenia (SL) (TLC nadir < 500 cells/μL), which occurred at a median of the 5th week following RT initiation, not at the completion of RT or upon treatment with maximal doses. SL risk was increased over the first 5 weeks (odds ratio [OR] = 3.455, P = 0.007), after which, no increased risk was observed (OR = 0.562, P = 0.216). The median TLCs remained low and failed to recover to the initial normal values of their pre-RT level after 2 months of RT completion. Patients without SL exhibited significantly improved progression-free survival (hazard ratio [HR] = 0.544, P = 0.010) and overall survival (HR = 0.463, P = 0.011) after controlling for confounding variables in multivariate analyses. The incidence of SL was significantly lower (71.1% reduction in risk (OR = 0.289, P = 0.007)) in patients who received hypofractionated RT with an OTT within 4 weeks, compared to those who had an OTT of more than 4 weeks (32.1% vs 62.1%, P = 0.006). Multivariate analyses revealed that OTT within 4 weeks (OR = 0.322, P = 0.032) was significantly associated with a decreased risk of developing SL after controlling for confounding factors. CONCLUSIONS: Hypofractionated RT was significantly associated with a decreased risk of SL and improved survival during definitive radiotherapy for unresectable stage III NSCLC.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zhao Q, Chen G, Ye L, et al. Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC. Radiat Oncol. 2019. PMID: 31133034. doi:10.1186/s13014-019-1287-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。